TEZSPIRE — Total revenues
Products & Services · Total revenuesAmgen TEZSPIRE — Total revenues remained flat by 0.0% to $369.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 52.1%, from $243.00M to $369.50M. Over 2 years (FY 2023 to FY 2025), TEZSPIRE — Total revenues shows an upward trend with a 61.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful commercial execution, or expanded clinical indications for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in physician prescribing patterns.
Detailed definition
This metric represents the total gross sales generated by the specific therapeutic product line within the company's por...
Peer comparison
Comparable to product-specific revenue reporting in other biopharmaceutical companies, often benchmarked against consensus estimates for key growth drivers and blockbusters.
amgn_segment_tezspire_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $567.00M | $972.00M | $1.48B |
| YoY Change | — | +71.4% | +52.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's tezspire — total revenues?
- Amgen (AMGN) reported tezspire — total revenues of $369.50M in Q4 2025.
- How has Amgen's tezspire — total revenues changed year-over-year?
- Amgen's tezspire — total revenues increased by 52.1% year-over-year, from $243.00M to $369.50M.
- What is the long-term trend for Amgen's tezspire — total revenues?
- Over 2 years (2023 to 2025), Amgen's tezspire — total revenues has grown at a 61.5% compound annual growth rate (CAGR), from $567.00M to $1.48B.
- What does tezspire — total revenues mean?
- The total revenue generated from sales of the specific therapeutic product.